UBX-303 / Ubix Therap - LARVOL DELTA

A PHASE IA/IB OPEN-LABEL STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMIC OF UBX-303061 IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES (ICML 2025) - P1 | "This phase will assess the suitability of the Recommended Dose for Expansion and explore the potential for indication-specific dose optimization. Enrollment is ongoing in the United States, South Korea and Poland (NCT06590961)."

Clinical • IO biomarker • P1 data • PK/PD data • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • HCK • LYN • MYD88

'TPD Platform Leader' Ubix Therapeutics Attracts 25.7 Billion Won in Investment [Google translation] (Hankyung) - "Ubix Therapeutics announced on the 23rd that it has completed a pre-IPO investment of 25.7 billion won....'The funds secured from this pre-IPO will be used for commercialization, including clinical trials in the US and Korea for UBX-303-1, expansion of new pipelines, and technology transfer, and we plan to accelerate preparations for an IPO targeting the second half of 2025.'"

Financing • Hematological Malignancies

Ubix, TPD treatment approved in phase 1 IND in Korea following US [Google translation] (Hankyung) - "Ubix Therapeutics announced on the 19th that its targeted protein degradation (TPD)-based blood cancer treatment candidate 'UBX-303-1' received approval for a phase 1a/1b clinical trial plan (IND) from the Ministry of Food and Drug Safety...Ubix has also submitted a clinical trial plan (CTA) to the European Medicines Agency (EMA) to promote a multinational, multi-institutional clinical trial of UBX-303-1....The company said that a total of 12 clinical institutions in Korea, the US, and Poland have been selected, and they plan to begin full-scale safety, pharmacokinetics, and pharmacodynamics evaluations of UBX-303-1 in patients with relapsed and refractory B-cell malignant lymphoma, starting with the first patient administration as early as October."

New P1 trial • Hematological Malignancies • Lymphoma • Oncology

Ubik Therapeutics, Korea's first TPD clinical trial… Announced at the American AACR [Google translation] (Hankyung) - "Ubix Therapeutics will present non-clinical research results and phase 1 clinical trial plans for UBX-303-1, a new drug candidate for blood cancer treatment, at the American Association for Cancer Research (AACR), which will be held in San Diego from the 5th to the 10th of next month (local time). It was announced on the 7th that it would announce....Ubix Therapeutics received approval for the clinical trial designation (IND) for UBX-303-1 from the U.S. Food and Drug Administration (FDA) at the end of last year and is planning to begin recruiting patients for clinical trials within the first half of this year....In addition to UBX-303-1, major pipelines include UBX-103, a prostate cancer treatment candidate undergoing non-clinical development with the goal of starting clinical trials in the first half of 2025..."

New P1 trial • New trial • Preclinical • Genito-urinary Cancer • Hematological Malignancies • Oncology • Prostate Cancer • Solid Tumor